Table 7.

Per-population results of the sensitivity analysis covering all PICOSTEPS components (€)

Analysis	Cladribine tablets	Fingolimod (difference to cladribine tablets)	Natalizumab (difference to cladribine tablets)	Treatment mix (difference to cladribine tablets)
Base case	19,995,689	4,598,742	16,249,701	6,928,934
50% of patients women	20,291,004	4,303,427	15,954,386	6,633,619
90% of patients women	19,754,067	4,840,363	16,491,322	7,170,555
Age of the population 36 years	20,323,777	4,270,654	15,921,613	6,600,845
Patient weight based on Finnish real-life distribution	20,178,296	4,416,134	16,067,093	6,746,326
Annual adherence drop 10% after 1st year	19,033,150	2,038,510	12,049,898	4,040,788
No screening costs	19,822,386	4,631,370	16,280,555	6,961,207
Time horizon 3 years	19,875,290	− 1,282,280	7,314,798	437,136
Fingolimod utilization: 14 28-tablet packs during the 1st year, 13 packs thereafter	19,995,689	4,930,645	16,249,701	7,194,456
Natalizumab utilization: 14 administrations during the 1st year, 13 administrations thereafter	19,995,689	4,598,742	19,951,070	7,669,207
Cost of natalizumab administration €934.50	19,995,689	4,598,742	24,645,460	8,608,085
Cost of natalizumab administration €373.00	19,995,689	4,598,742	17,098,900	7,098,773
All cost inputs −20%	15,996,551	3,678,993	12,999,761	5,543,147
All cost inputs +20%	23,994,826	5,518,490	19,499,641	8,314,720
24% of cladribine users assumed to switch to fingolimod on the fourth year	21,548,433	3,045,997	14,696,957	5,376,189
Direct costs only	19,890,489	4,541,817	15,650,099	6,763,473
Direct costs only, no travelling costs	19,823,970	4,514,509	15,145,366	6,640,680